ArsenalBio develops programmable CAR T-cell therapies specifically targeting solid tumors, utilizing a computationally driven approach to enhance treatment efficacy. The company addresses the challenge of treating cancer's complex nature by engineering cell therapies that aim to improve patient outcomes.
Funding
$630.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Solid tumors present a complex challenge for traditional cancer therapies due to their heterogeneous nature and immunosuppressive microenvironment. Existing CAR T-cell therapies have shown limited efficacy against solid tumors, struggling to effectively penetrate the tumor mass, maintain activity within the tumor microenvironment, and avoid off-target toxicities.
Solution
ArsenalBio is developing programmable CAR T-cell therapies designed to overcome the limitations of treating solid tumors. Their approach leverages computational biology and synthetic biology to engineer cell therapies with enhanced functionality. These engineered cells are designed to more effectively target and eliminate cancer cells within the tumor microenvironment, while also minimizing off-target effects. The company aims to improve patient outcomes by creating cell therapies that can address the multifaceted challenges posed by solid tumors.
Target Audience
The primary target audience includes patients with solid tumors who have not responded to traditional cancer treatments, as well as oncologists and hematologists seeking more effective cell therapy options.
Features
- Computationally driven design process for identifying optimal CAR T-cell constructs.
- Synthetic biology approaches to enhance CAR T-cell functionality, including improved tumor penetration and persistence.
- Programmable cell therapies designed to overcome the immunosuppressive tumor microenvironment.
- Development of cell therapies with reduced off-target toxicity profiles.